MXPA05003355A - Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino. - Google Patents

Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.

Info

Publication number
MXPA05003355A
MXPA05003355A MXPA05003355A MXPA05003355A MXPA05003355A MX PA05003355 A MXPA05003355 A MX PA05003355A MX PA05003355 A MXPA05003355 A MX PA05003355A MX PA05003355 A MXPA05003355 A MX PA05003355A MX PA05003355 A MXPA05003355 A MX PA05003355A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
methanesulfonate hemihydrate
sibutramine methanesulfonate
crystalline sibutramine
crystalline
Prior art date
Application number
MXPA05003355A
Other languages
English (en)
Inventor
Ghang Young-Kil
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2003-0053752A external-priority patent/KR100536750B1/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MXPA05003355A publication Critical patent/MXPA05003355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Metallurgy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se relaciona con una composicion farmaceutica para tratar o prevenir la obesidad, que comprende semihidrato de metansulfonato de sibutramina cristalino de la formula (I). El semihidrato de metansulfonato de sibutramina cristalino de conformidad con la presente invencion tiene una solubilidad en agua muy superior, y estabilidad mejorada bajo una condicion de humedad/temperatura elevada, en comparacion con monohidrato de hidrocloruro de sibutramina. (ver formula (I)).
MXPA05003355A 2002-10-05 2003-09-25 Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino. MXPA05003355A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20020060798 2002-10-05
KR10-2003-0053752A KR100536750B1 (ko) 2002-10-05 2003-08-04 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
PCT/KR2003/001955 WO2004030663A1 (en) 2002-10-05 2003-09-25 Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate

Publications (1)

Publication Number Publication Date
MXPA05003355A true MXPA05003355A (es) 2005-10-18

Family

ID=36147018

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003355A MXPA05003355A (es) 2002-10-05 2003-09-25 Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.

Country Status (14)

Country Link
US (1) US6900245B2 (es)
EP (1) EP1545484A4 (es)
JP (1) JP4278652B2 (es)
AU (1) AU2003264968B2 (es)
BR (1) BR0315084A (es)
CA (1) CA2501321C (es)
HK (1) HK1083741A1 (es)
HR (1) HRP20050307A2 (es)
MX (1) MXPA05003355A (es)
NO (1) NO20052222L (es)
NZ (1) NZ538966A (es)
PL (1) PL375032A1 (es)
RU (1) RU2290924C2 (es)
WO (1) WO2004030663A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
JP4934293B2 (ja) * 2005-07-05 2012-05-16 コスモ石油株式会社 植物活力剤組成物
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
KR100806673B1 (ko) 2006-06-23 2008-03-03 주식회사 대희화학 결정상 시부트라민 프리베이스의 제조방법
KR20100088992A (ko) * 2009-02-02 2010-08-11 주식회사 대희화학 (ｒ)-시부트라민 염 및 그의 제조방법
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
CN102786444A (zh) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 一种西布曲明类似物的磺酸盐的制备方法
EP3185900A4 (en) * 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2098302B (en) * 1981-05-13 1985-02-06 Fort Vale Eng Ltd Improvements in lids for pressure vessels
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
WO2000056309A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
AU3757300A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating anxiety disorders
AU3895300A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
JP2002539251A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 治療薬に伴う体重増加を調節する方法
CN1161114C (zh) * 1999-03-19 2004-08-11 艾博特股份有限两合公司 一种治疗睡眠障碍的化合物在制药中的用途
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6232347B1 (en) * 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
AU2002210816A1 (en) * 2000-11-02 2002-05-15 Torrent Pharmaceuticals Ltd Process for preparation of beta-phenethylamine derivative

Also Published As

Publication number Publication date
PL375032A1 (en) 2005-11-14
CA2501321A1 (en) 2004-04-15
US20040068018A1 (en) 2004-04-08
JP2006506449A (ja) 2006-02-23
NO20052222L (no) 2005-05-06
EP1545484A1 (en) 2005-06-29
HK1083741A1 (en) 2006-07-14
JP4278652B2 (ja) 2009-06-17
AU2003264968B2 (en) 2006-03-16
WO2004030663A1 (en) 2004-04-15
NZ538966A (en) 2006-11-30
US6900245B2 (en) 2005-05-31
CA2501321C (en) 2008-07-08
EP1545484A4 (en) 2010-01-13
RU2290924C2 (ru) 2007-01-10
BR0315084A (pt) 2005-08-16
RU2005109560A (ru) 2005-09-20
AU2003264968A1 (en) 2004-04-23
HRP20050307A2 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
TW200716589A (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
GEP20104895B (en) Preparation of pregabalin and related compounds
HRP20050307A2 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
HK1079522A1 (en) Thienyl compounds
HK1080470A1 (en) Heterocyclic compounds
SE0202463D0 (sv) Novel compounds
MY135841A (en) Novel benzodioxoles
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
TW200630374A (en) Thiazolyldihydroindazoles
TW200626601A (en) Novel compounds
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
HK1048474A1 (en) Substituted thiene-3-yl-sulfonyl amino(thio)carbonyl-triazolin(thi)ones.
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
TW200635916A (en) Compounds
IL164516A0 (en) 2,6-Quimolinyl and 2,6-naphthyl derivatives, processes for preparation them and their uses as vla-4 inhibitors
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
GB0314967D0 (en) Piperazine derivatives
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
NO20080144L (no) Spiro-benzimidazoler som inhibitorer av magesyre og sekresjon

Legal Events

Date Code Title Description
FG Grant or registration